US Deprescribing Research Network Annual Meeting

#USDEN2020

Welcome!

US Deprescribing Research Network

2020 Virtual Annual Meeting

Tuesday, October 6, 2020
12:00pm - 3:30pm ET

Advancing research to optimize medication use among older adults

Disclosures and Acknowledgements

- Funded by NIA (R24 AG064025)
- American Geriatrics Society, UpToDate

- Thank you!
  - Malena Spar, Jonathan Norton, Anael Rizzo, Gabrielle Schiller, Geraldine Puerto, Tony Teano
  - Speakers, discussants, small group moderators
  - Scientific Advisory Board
  - International partners
  - Marcel Salive
  - National Institute on Aging

Agenda

12:00 – 12:15	Welcome Address *- Michael Steinman, MD and Cynthia Boyd, MD, MPH*
12:15 – 1:00	Keynote: Is it time to reimagine deprescribing research? *- Cara Tannenbaum, MD, MSc*
1:00 – 1:45	Small Group Breakouts
1:45 – 2:15	Break
2:15 – 3:00	Updates in Deprescribing Research *- Amy Linsky, MD, MSc and Kristin Zimmerman, PharmD*
3:00 – 3:20	Updates in Deprescribing Funding Opportunities *- Marcel Salive, MD, MPH*
3:20 – 3:30	Closing Remarks *- Cynthia Boyd, MD, MPH and Michael Steinman, MD*

All sessions will have Q&A

What is the network?

US Deprescribing Research Network

You !!!

Our goal is to help you

Investigator Development

Community, collaborations, education, career development

- Webinars
- Junior investigator intensive
  - Applications due February 2021
- Collaboration grants
  - Rolling review – apply now!
- Annual meeting



What is the Junior Investigator Intensive Program?

The program has 3 main components:

1. Scholars will attend a virtual special evening meeting following the US Deprescribing Research Network Annual Meeting on May 6, 2020 that is focused on career development, networking, and collaborative research opportunities for early-stage investigators interested in deprescribing. ***Due to the COVID-19 pandemic and the postponement of the Annual Meeting, the content of this evening meeting will be incorporated into the monthly web-based meetings over the course of the year***
2. Scholars will attend monthly web-based meetings over the following year that combine a mix of opportunities to get feedback on your research from colleagues and senior researchers and discussion of collaborative research projects in which scholars can participate (and help lead).
3. Scholars will have access to other aspects of the US Deprescribing Research Network such as attendance at webinars, consultations, and a variety of other resources. Scholars will be expected to attend the virtual USDeN Annual Meeting and most of the monthly web-based meetings in the year following.



US Deprescribing Research Network

Advancing Research to Optimize Medication Use Among Older Adults

Collaboration Mini Awards

Pilot and Grant Planning Awards

Support early-stage research in deprescribing that has high potential to develop into future large projects

- Pilot awards
- Grant planning awards
- $60K funds over 1 year
- Non-US are eligible
- Applications due January 2021



US Deprescribing Research Network

Advancing Research to Optimize Medication Use Among Older Adults

Investigator Initiated Proposal Guidelines (USDeN IIP 2020)

The U.S. Deprescribing Research Network is a collaborative research network with the overall goal to support development of investigators studying deprescribing for older adults and to catalyze a range of high-quality, clinically impactful research in this area. The challenges of excessive medication use, medication-related harms, and values-driven decision-making are especially pressing for older adults, particularly those with multiple chronic conditions. Solutions to these challenges require attention to geriatric principles, including (but not limited to) clinical complexity and multimorbidity, transitions across multiple providers and sites of care, older adults' values and priorities, and the shifting balance of medication benefits and harms in late life. Our overarching aim is to expand the quality, quantity, and translational impact of deprescribing research. Pilot grants up to $60,000 in total costs (direct plus indirect funds) for a one-year period will be awarded to applicants seeking to further research efforts in this field as detailed in the following sections.

1) **Background:** Deprescribing is an essential component of safe and effective health care for older adults. Even with the most intensive efforts, it is difficult to prevent older adults from being started on medications that may cause more harm than benefit. In addition, medications that were once helpful for older adults may no longer be advisable to continue, either because the person has developed adverse effects, or because their clinical conditions, overall health, and/or goals of care may have changed since the medication was first prescribed.

2) **Research Objectives**: This funding opportunity is for studies designed to expand the quality, quantity, and translational impact of deprescribing research targeting older adults. Funding will be provided primarily, but not exclusively, to junior investigators whose studies provide key preliminary data, proof of concept, or developmental work that provides a clear pathway to future, larger-scale studies.

3) **Population of interest:** The study must focus on deprescribing efforts impacting older adults and may include an emphasis on patients with multiple chronic conditions, including those with special vulnerabilities, such as dementia.

4) **Research Methodology:** Research is needed in a broad range of areas which include, but are not limited to, delineating the clinical outcomes of deprescribing, identifying behavioral and communication techniques that can constructively engage patients on this topic, determining the effectiveness of deprescribing interventions, and addressing the needs of underserved groups. Different study designs are needed to answer these questions – from pilot research that may lead to future clinical trials, to observational studies, to in-depth qualitative evaluation.

5) **Funds available:** Maximum period of performance is one year. The anticipated total award (directs + indirects) for this grant opportunity is a maximum of $60,000. If indirect cost rates have been negotiated, indirect costs are to be budgeted in accordance with the organization's negotiated rate. The combined budgeted total costs will not exceed $60,000 or use an indirect cost rate exceeding each organization's negotiated rate. The possibility of funding exceeding $60,000 or a period greater than one year may be considered with special permission; initiate such a request as early as possible through an email to admin@deprescribingresearch.org

RFA Investigator Initiated Proposal – November 2019

Stakeholder Engagement

Engage stakeholder and community partners to maximize relevance and impact of research on deprescribing

- Engage throughout activities of the network – pilot studies, webinars, dissemination
- Stakeholder council
- Messaging



Data and resources

Develop resources and provide supports to advance research on deprescribing

- Compendia and repositories
  - Repository of DSMB & IRB materials
- Data development, harmonization, management
- Consultation services



Shed MEDS Data Safety Monitoring Board Report
-Closed Session-

A Randomized Controlled Trial To Deprescribe For Older Patients With Polypharmacy Transferred From The Hospital To Skilled Nursing Facilities

NIH Grant Number: RO1AG053264

Principal Investigators:
Sandra Simmons, PhD
Eduard Vasilevskis, MD

DO NOT REUSE

Working Groups

Create high-value resources to enhance deprescribing research

- High-value targets for deprescribing
- Measures used in deprescribing research
- Data harmonization collaborative
- Deprescribing communication

DeprescribingResearch.org



@DeprescribeUS

Please reach out – our goal is to help you